<DOC>
	<DOC>NCT01017731</DOC>
	<brief_summary>The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.</brief_summary>
	<brief_title>Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes</brief_title>
	<detailed_description>The primary purpose of this study is to determine if treatment with ramucirumab causes prolongation of the QTc/QT interval in participants with advanced cancer, to assess the safety and tolerability of ramucirumab therapy, and to evaluate the pharmacokinetic (PK) characteristics of ramucirumab</detailed_description>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>The participant has histologically documented advanced or metastatic malignant cancer of solid tumor origin which has not responded to standard therapy or for which no standard therapy is available The participant has resolution of adverse events from prior anticancer therapies Performance status of 0 to 2 The participant is ≥ 18 years of age The participant is able to provide informed written consent and is amenable to compliance with protocol schedules and testing The participant has adequate liver, kidney, blood, and blood clotting functions as defined in trial entrance criteria The participant agrees to use adequate contraception during the study period and for 8 weeks after the last dose of study treatment The participant had anticancer therapy within 14 days (6 weeks for nitrosoureas or mitomycin C) prior to entering the study The participant had therapeutic radiotherapy within 14 days prior to entering the study The participant has ongoing side effects ≥ Grade 2 due to prior anticancer therapy The participant has brain or leptomeningeal metastases The participant has a history of uncontrolled or severe cardiac disease The participant has a history of severe congestive heart failure (CHF) The participant has a known history of arterial thrombotic events The participant has a known history of significant peripheral arterial disease (PAD) The participant has an implantable pacemaker or automatic implantable cardioverter defibrillator (AICD) The participant has a history of risk factors for ventricular tachycardia or Torsades de pointes (TdP) [for example, family history (parents or siblings) of long QT syndrome], history of fainting, unexplained loss of consciousness, or convulsions The participant has a systolic blood pressure (SBP) of &gt; 150 millimeters of mercury (mmHg) or &lt; 90 mmHg or a diastolic blood pressure (DBP) of &lt; 45 or &gt; 95 mmHg. (Participants with a history of hypertension who are receiving antihypertensive therapy are permitted on study provided blood pressure is within the parameters detailed above) The participant has a heart rate &lt; 50 beats per minute (bpm) or &gt; 100 bpm at rest The participant has a clinically relevant abnormality on the ECG, preventing an accurate measurement of the QT interval The participant is using a medication that is known to prolong the ECG QT interval The participant has a known allergy to any of the treatment components including fluoroquinolone antibiotics The participant has received an investigational new drug or device within 14 days prior to enrollment into this study (excluding placement of an intravenous access device) The participant has undergone major surgery within 28 days prior to enrollment The participant has known human immunodeficiency virus (HIV) infection The participant, if female, is pregnant or lactating The participant is receiving chronic daily treatment with aspirin [&gt; 325 milligrams per day (mg/day)] The participant has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, other noninvasive carcinoma, or in situ neoplasm The participant has psychological, familial, sociological, or geographical conditions which do not permit adequate study followup, compliance with the protocol, or signature of Informed Consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Advanced Solid tumor</keyword>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>QTc</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Malignant</keyword>
</DOC>